Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits

Abstract

Previous reports have highlighted the disparity in biocompatibility of two differently engineered heparin coatings during the cardiopulmonary bypass (CPB) procedure. The aim of this prospective study was to evaluate the impact of the difference in haemocompatibility provided by either the Duraflo II equipment or the Carmeda equipment in the terminal inflammatory response observed after coronary artery surgery.

Thirty patients were randomly allocated to two groups to be operated on using either Duraflo II equipment (group I) or Carmeda equipment (group 2) for extracorporeal circulation (ECC). Initial inflammatory response was assessed by terminal complement complex activation (SC5b-9). The late inflammatory response observed in the postoperative period was assessed by measuring cytokine production (tumour factor necrosis (TNFα), interleukin IL-6, interleukin IL-8) and circulating concentrations of adhesion molecules (ELAM-1, ICAM-1).

The release of SC5b-9 after CPB and after protamine administration was lower in group 2 than in group 1 (p = 0.0002 and p = 0.006, respectively). A significant production of cytokines was detected in both groups with peak values observed within the time range of 4-6 h after the start of CPB.

However, no difference was observed between the groups except for the IL-8 level in group 2, which was lower 2 h after the start of CPB (p = 0.01). Plasma levels of adhesion molecules were similar in both groups within the investigation period.

Although the Carmeda equipment was more effective in reducing complement activation, the late inflammatory response was similar using either the Duraflo II or Carmeda equipment for extracorporeal circulation as reflected by the changes of cytokine and circulating adhesion molecule levels.

Get full access to this article

View all access options for this article.

References

Edmunds LH. Blood-surface interactions during cardiopulmonary bypass . J Card Surg 1993; 8: 404-410 .

Wildevuur CRH. Blood damage and activation in cardiopulmonary bypass. In: Friedel N , Hetzer R , Royston D eds. Blood use in cardiac surgery. New York: Springer , 1991: 269-274.

Hornick P , George A. Blood contact activation: pathophysiological effects and therapeutic approaches . Perfusion 1996; 11: 3-19 .

Jansen PGM , te Velthuis H , Huybregts RAJM et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits . J Thorac Cardiovasc Surg 1995; 110: 829-834 .

Pekna M , Hagman L , Halden E , Nilsson UR , Nilsson B , Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin . Ann Thorac Surg 1994; 58 421-424 .

Videm V , Svennevig JL , Fosse E et al. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations . J Thorac Cardiovasc Surg 1992; 103: 806-813 .

Gu YJ , van Oeveren W , Akkerman C , Boonstra PW , Huyzen RJ , Wildevvur CRH. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass . Ann Thorac Surg 1993; 55: 917-922 .

Borowiec J. Thelin S , Bagge L , Nilsson L , Venge P. Hansson HE. Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass . J Thorac Cardiovasc Surg 1992; 104: 642-647 .

Weerwind PW , Maessen JG , van Tits LJH et al. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass . J Thorac Cardiovasc Surg 1995; 110: 1633-1641 .

10.

Steinberg BM , Grossi EA , Schwartz DS et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass . Ann Thorac Surg 1995; 60: 525-529 .

11.

Moen O , Fosse E , Brockmeier V et al. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems . Ann Thorac Surg 1995; 60: 1317-1323 .

12.

Ovrum E , Mollnes, TE , Fosse E et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits . J Thorac Cardiovasc Surg 1995; 110: 1623-1632 .

13.

Hsu LC. Principles of heparin-coating techniques . Perfusion 1991; 6: 209-219 .

14.

Larm O , Larsson R , Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue . Biomat Med Dev Artif Organs 1983; 11: 161-173 .

15.

Kazatchkine MD , Fearon DT , Metcalfe DD , Rosenberg RD , Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase . J Clin Invest 1981; 67: 223-228 .

16.

de Vroege R , Rutten PMMJ , Kalkman C et al. Biocompatibility of three different membrane oxygenators: effects on complement, neutrophil and monocyte activation . Perfusion 1997; 12: 369-375 .

17.

Jansen PGM , te Velthuis H , Oudemans-Van Straaten HM et al. Perfusion-related factors of endotoxin release during cardiopulmonary bypass . Eur J Cardiothorac Surg 1994; 8: 125-129 .

18.

Vukajlovitch SW , Hoffman J , Morrison DC. Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of the classical and alternative pathway . Mol Immunol 1987; 24: 319-332 .

19.

Steinberg JB , Kapelanski DP , Olson JD , Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass . J Thorac Cardiovasc Surg 1993; 106: 1008-1016 .

20.

Menasché P , Haydar S , Peynet J et al. A potential mechanism of vasodilation after warm heart surgery. The temperature-dependant release of cytokines . J Thorac Cardiovasc Surg 1994; 107: 293-299 .

21.

Frering B , Philip I , Dehoux M , Rolland C , Langlois JM , Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass . J Thorac Cardiovasc Surg 1994; 108: 636-641 .

22.

Deng MC , Wiedner M , Erren M , Möllhoff T , Assmann G , Scheld HH. Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics . Eur J Cardiothorac Surg 1995; 9: 22-29 .

23.

Casey LC. Role of cytokines in the pathogenesis of cardiopulmonary-induced multisystem organ failure . Ann Thorac Surg 1993; 56: S92-S96 .

24.

Hennein HA , Ebba H , Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization . J Thorac Cardiovasc Surg 1994; 108: 626-635 .

25.

Menasché P , Peynet J. Haeffner-Cavaillon N et al. Influence of temperature on neutrophil trafficking during clinical cardiopulmonary bypass . Circulation 1995; 92(suppl II): II334-II340 .

26.

Boonstra PW , van Imhoff GW , Eijsman L et al. Reduced platelet activation and improved hemostasis after controlled cardiotomy suction during clinical membrane oxygenator perfusions . J Thorac Cardiovasc Surg 1985; 89: 900-990 .

27.

Tabuchi N , de Haan J , Boonstra PW , van Oeveren W. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass . J Thorac Cardiovasc Surg 1993; 106: 828-833 .

28.

Le Deist F , Menasché P , Kucharski C , Bel A , Piwnica A , Bloch G. Hypothermia during cardiopulmonary bypass delays but does not prevent neutrophil-endothelial cell adhesion. A clinical study . Circulation 1995; 92: 354-358 .

29.

Boldt J , Osmer C , Schindler E , Linke LC , Stertmann WA , Hempelmann G. Circulating adhesion molecules in cardiac operations: influence of high-dose aprotinin . Ann Thorac Surg 1995; 59: 100-105 .

30.

Ashraf S , Tian Y , Cowan D et al. ‘Low-dose’ aprotinin modifies hemostasis but not proinflammatory response . Ann Thorac Surg 1997; 63: 68-73 .